Log In
Print
BCIQ
Print
Print this Print this
 

Akynzeo, netupitant/palonosetron (NEPA) (formerly Netu-palo-FDC)

  Manage Alerts
Collapse Summary General Information
Company Helsinn Healthcare S.A.
DescriptionFixed-dose combination of 300 mg netupitant, a neurokinin 1 (NK1) Substance P receptor antagonist, and 0.5 mg palonosetron, a selective serotonin (5-HT3) receptor antagonist
Molecular Target Neurokinin 1 (NK1) Substance P receptor (TACR1) ; Serotonin (5-HT3) receptor
Mechanism of ActionNeurokinin-1 (NK-1) (Substance P) receptor antagonist; Serotonin (5-HT3) receptor antagonist
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationEmesis
Indication DetailsPrevent acute and delayed chemotherapy-induced nausea and vomiting (CINV); Prevent chemotherapy-induced nausea and vomiting (CINV)
Regulatory Designation U.S. - Special Protocol Assessment (Prevent chemotherapy-induced nausea and vomiting (CINV));
U.S. - Standard Review (Prevent acute and delayed chemotherapy-induced nausea and vomiting (CINV));
EU - Standard Review (Prevent acute and delayed chemotherapy-induced nausea and vomiting (CINV))
Partner Chugai Pharmaceutical Co. Ltd.; CJ Group; Eisai Co. Ltd.; Especificos Stendhal S.A. de C.V.; Galenica Ltd.; Mundipharma International Ltd.; Riemser Arzneimittel AG; Taiho Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

8

$8.9M

$0.6M

$3.2M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today